| Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site G Weitz-Schmidt, K Welzenbach, V Brinkmann, T Kamata, J Kallen, ... Nature medicine 7 (6), 687-692, 2001 | 1434 | 2001 |
| Structural basis for LFA-1 inhibition upon lovastatin binding to the CD11a I-domain J Kallen, K Welzenbach, P Ramage, D Geyl, R Kriwacki, G Legge, ... Journal of molecular biology 292 (1), 1-9, 1999 | 328 | 1999 |
| Novel immunomodulator FTY720 is phosphorylated in rats and humans to form a single stereoisomer. Identification, chemical proof, and biological characterization of the … R Albert, K Hinterding, V Brinkmann, D Guerini, C Müller-Hartwieg, ... Journal of medicinal chemistry 48 (16), 5373-5377, 2005 | 196 | 2005 |
| The potent protein kinase C-selective inhibitor AEB071 (sotrastaurin) represents a new class of immunosuppressive agents affecting early T-cell activation JP Evenou, J Wagner, G Zenke, V Brinkmann, K Wagner, J Kovarik, ... Journal of Pharmacology and Experimental Therapeutics 330 (3), 792-801, 2009 | 184 | 2009 |
| ADAM17 is the main sheddase for the generation of human triggering receptor expressed in myeloid cells (hTREM2) ectodomain and cleaves TREM2 after Histidine 157 D Feuerbach, P Schindler, C Barske, S Joller, E Beng-Louka, ... Neuroscience letters 660, 109-114, 2017 | 135 | 2017 |
| Small molecule inhibitors induce conformational changes in the I domain and the I-like domain of lymphocyte function-associated antigen-1: molecular insights into integrin … K Welzenbach, U Hommel, G Weitz-Schmidt Journal of Biological Chemistry 277 (12), 10590-10598, 2002 | 107 | 2002 |
| Improved lymphocyte function-associated antigen-1 (LFA-1) inhibition by statin derivatives: molecular basis determined by x-ray analysis and monitoring of LFA-1 conformational … G Weitz-Schmidt, K Welzenbach, J Dawson, J Kallen Journal of Biological Chemistry 279 (45), 46764-46771, 2004 | 98 | 2004 |
| CD47 fusion protein targets CD172a+ cells in Crohn’s disease and dampens the production of IL-1β and TNF N Baba, VQ Van, K Wakahara, M Rubio, G Fortin, B Panzini, G Soucy, ... Journal of Experimental Medicine 210 (6), 1251-1263, 2013 | 60 | 2013 |
| 1, 4-Diazepane-2, 5-diones as novel inhibitors of LFA-1 S Wattanasin, J Kallen, S Myers, Q Guo, M Sabio, C Ehrhardt, R Albert, ... Bioorganic & medicinal chemistry letters 15 (4), 1217-1220, 2005 | 54 | 2005 |
| A statin‐based inhibitor of lymphocyte function antigen‐1 protects against ischemia/reperfusion‐induced leukocyte adhesion in the colon MX Wan, R Schramm, D Klintman, K Welzenbach, G Weitz‐Schmidt, ... British journal of pharmacology 140 (2), 395-401, 2003 | 42 | 2003 |
| Intracellular Phospho‐Flow cytometry reveals novel insights into TCR proximal signaling events. A comparison with Western blot A Haas, G Weckbecker, K Welzenbach Cytometry Part A: The Journal of the International Society for Analytical …, 2008 | 34 | 2008 |
| 1, 4-Diazepane-2-ones as novel inhibitors of LFA-1 S Wattanasin, R Albert, C Ehrhardt, D Roche, M Sabio, U Hommel, ... Bioorganic & medicinal chemistry letters 13 (3), 499-502, 2003 | 31 | 2003 |
| Statin-derived 1, 3-oxazinan-2-ones as submicromolar inhibitors of LFA-1/ICAM-1 interaction: stabilization of the metabolically labile vanillyl side chain T Ullrich, K Baumann, K Welzenbach, S Schmutz, G Camenisch, ... Bioorganic & medicinal chemistry letters 14 (10), 2483-2487, 2004 | 29 | 2004 |
| Diazacycloalkanedione derivatives R Albert, J Dawson, C Ehrhardt, S Wattanasin, G Weitz-Schmidt, ... US Patent 6,642,225, 2003 | 26 | 2003 |
| Soluble polypeptides for use in treating autoimmune and inflammatory disorders M Raymond, M Sarfati, K Welzenbach, M Woisetschlaeger US Patent App. 13/132,400, 2011 | 23 | 2011 |
| Phosphorylation by sphingosine kinase 2 is essential for in vivo potency of FTY720 analogues K Hogenauer, A Billich, C Pally, M Streiff, T Wagner, K Welzenbach, ... ChemMedChem 3 (7), 1027, 2008 | 22 | 2008 |
| Targeting SIRP‐α protects from type 2‐driven allergic airway inflammation M Raymond, V Quang Van, M Rubio, K Welzenbach, M Sarfati European journal of immunology 40 (12), 3510-3518, 2010 | 21 | 2010 |
| Soluble proteins for use as therapeutics T Huber, F Kolbinger, M Sarfati, K Welzenbach US Patent App. 13/517,989, 2013 | 19 | 2013 |
| ENZYMATIC & CELLULAR CHARACTERIZATION OF NVPAEB071 (AEB), A NOVEL & SELECTIVE PROTEIN KINASE C (PKC) INHIBITOR THAT BLOCKS EARLY T CELL ACTIVATION, AND ITS USE TO DEFINE THE … JP Evenou, V Brinkmann, H Towbin, K Welzenbach, S Cottens, J Wagner, ... Transplantation 82 (1), 1026, 2006 | 12 | 2006 |
| Substituted 2-oxo-1, 4-diazacycloalkanes R Albert, JG Meingassner, S Wattanasin, G Weitz-Schmidt, K Welzenbach, ... US Patent 6,399,599, 2002 | 12 | 2002 |
